Repligen (NASDAQ:RGEN) Coverage Initiated at Canaccord Genuity Group

Canaccord Genuity Group initiated coverage on shares of Repligen (NASDAQ:RGEN - Free Report) in a report issued on Tuesday morning, MarketBeat Ratings reports. The brokerage issued a hold rating and a $165.00 price objective on the biotechnology company's stock.

Several other analysts have also weighed in on the stock. Royal Bank of Canada reiterated an "outperform" rating and set a $205.00 target price on shares of Repligen in a research note on Thursday, September 26th. Wolfe Research initiated coverage on shares of Repligen in a report on Thursday, November 14th. They set a "peer perform" rating for the company. Wells Fargo & Company initiated coverage on shares of Repligen in a report on Tuesday, August 27th. They set an "overweight" rating and a $180.00 price target for the company. Finally, StockNews.com raised shares of Repligen from a "sell" rating to a "hold" rating in a report on Friday, November 22nd. Six investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $185.20.

Repligen Stock Down 1.7 %

Shares of NASDAQ:RGEN traded down $2.78 during midday trading on Tuesday, reaching $158.14. The company had a trading volume of 519,345 shares, compared to its average volume of 655,789. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The stock's fifty day moving average price is $143.15 and its 200-day moving average price is $141.68. The stock has a market capitalization of $8.86 billion, a P/E ratio of -427.14, a PEG ratio of 4.64 and a beta of 0.96. Repligen has a one year low of $113.50 and a one year high of $211.13.

Repligen (NASDAQ:RGEN - Get Free Report) last released its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The firm had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. During the same quarter in the previous year, the firm earned $0.23 earnings per share. The firm's revenue for the quarter was up 9.7% compared to the same quarter last year. Equities research analysts expect that Repligen will post 1.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Repligen

Several institutional investors have recently bought and sold shares of RGEN. Toronto Dominion Bank raised its holdings in Repligen by 1.5% during the 2nd quarter. Toronto Dominion Bank now owns 5,207 shares of the biotechnology company's stock worth $656,000 after buying an additional 75 shares during the period. DekaBank Deutsche Girozentrale raised its holdings in Repligen by 1.1% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 7,839 shares of the biotechnology company's stock worth $982,000 after buying an additional 89 shares during the period. MML Investors Services LLC raised its holdings in Repligen by 2.7% during the 3rd quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company's stock worth $503,000 after buying an additional 89 shares during the period. Ballentine Partners LLC increased its holdings in shares of Repligen by 6.2% in the 3rd quarter. Ballentine Partners LLC now owns 1,807 shares of the biotechnology company's stock valued at $269,000 after purchasing an additional 105 shares during the period. Finally, CWM LLC increased its holdings in shares of Repligen by 36.3% in the 3rd quarter. CWM LLC now owns 428 shares of the biotechnology company's stock valued at $64,000 after purchasing an additional 114 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.